Nutriband Inc. NTRB Archives

WednesdayDec 31, 2025 9:20 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Issues Shareholder Letter Highlighting 2025 Milestones and 2026 Outlook

Nutriband (NASDAQ: NTRB) announced that Chief Executive Officer Gareth Sheridan has published a letter to shareholders outlining key achievements during 2025 and providing perspective on the Company’s priorities and outlook for 2026. The update highlighted Nutriband’s continued focus on shareholder value, including disciplined capital management, a 25% preferred stock dividend issued in 2025, and progress toward reducing share price volatility with the expiration of IPO-era warrants in October 2026. The Company also detailed significant advances for its lead product, AVERSA(TM) Fentanyl, which is being developed as an abuse-deterrent opioid transdermal patch. During 2025, Nutriband strengthened its intellectual property portfolio with…

MondayDec 29, 2025 10:10 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Sells 90% Stake in Pocono Pharmaceutical for $5 Million

Nutriband (NASDAQ: NTRB) announced that it has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million, while retaining a 10% ownership interest following the transaction. The company said proceeds from the sale will be used to support continued development of AVERSA Fentanyl, a transdermal opioid patch designed to deter abuse, misuse, and accidental exposure, which Nutriband believes has the potential to become the world’s first abuse-deterrent fentanyl patch and generate estimated annual U.S. sales of $80 million to $200 million. To view the full press release, visit https://ibn.fm/Bg52W About Nutriband…

MondayNov 24, 2025 9:40 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Chairman Presentation at NobleCon21

Nutriband (NASDAQ: NTRB) announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets’ annual emerging growth equity conference, on Dec. 3 at 9:30 a.m. Eastern at Florida Atlantic University’s Executive Education Complex in Boca Raton, Florida. Investors and guests may attend at a discounted rate using code NTRBNOBLECON, and a high-definition webcast will be available the following day at nobleconference.com and Channelchek.com, where it will remain archived for 90 days. To view the full press release, visit https://ibn.fm/3Stl6 About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our…

FridayOct 10, 2025 9:00 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Partners with Brand Institute to Develop Global Brand Identity for AVERSA FENTANYL

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced that its subsidiary 4P Therapeutics has signed an agreement with Brand Institute, Inc., a global leader in pharmaceutical brand name and identity development, to create the worldwide commercial brand name and visual identity for AVERSA FENTANYL, the company’s lead product utilizing its AVERSA(TM) abuse-deterrent transdermal technology. Designed to deter misuse and reduce accidental opioid exposure, AVERSA FENTANYL could become the world’s first abuse-deterrent opioid patch. Brand Institute, with a 75% share of global drug name approvals and 87% of FDA-approved names in 2024, will lead the initiative alongside its…

ThursdayOct 09, 2025 9:00 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Files Provisional Patent to Strengthen Protection of AVERSA(TM) Abuse-Deterrent Technology

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the filing of a provisional patent application with the U.S. Patent and Trademark Office to expand protection for its AVERSA(TM) abuse-deterrent transdermal technology. The filing covers improved aversive formulations and coating application methods designed to enhance abuse deterrence and increase resistance to tampering. If converted to a non-provisional patent and granted, the new patent could extend AVERSA’s protection by up to 20 years from the filing date. AVERSA(TM) technology, already patented in 46 countries, incorporates aversive agents into transdermal patches to prevent misuse of drugs with abuse potential while…

WednesdayOct 08, 2025 9:55 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Nutriband (NASDAQ: NTRB) announced that Chairman Serguei Melnik will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Wednesday, Oct. 8, 2025, at 3 p.m. ET. The presentation will include a fireside Q&A session with questions from the live virtual audience, and registered investors can also schedule one-on-one meetings with Melnik. Interested attendees can register at no cost via the conference’s official site. A video webcast of the presentation will be available on Channelchek, Noble’s investor portal, and archived for 90 days on both Channelchek.com and Nutriband’s website. To view the full press release, visit https://ibn.fm/UjUSO About Nutriband…

ThursdaySep 25, 2025 9:30 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at MicroCap Rodeo Conference

Nutriband (NASDAQ: NTRB) announced it will participate in the MicroCap Rodeo Conference in New York City on Sept. 25, 2025. Company Chairman Serguei Melnik will present at 10 a.m., discussing operational highlights, growth initiatives, and the strategic direction for its AVERSA platform technology. The presentation will be webcast live, with registration available for interested parties. To view the full press release, visit https://ibn.fm/Lb7oM About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated…

FridaySep 19, 2025 1:26 pm

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Eyes Clear Development Pathway for AVERSA(TM) Technology

Nutriband (NASDAQ: NTRB) is a transdermal pharmaceutical developer that has secured crucial FDA engagement for its lead abuse-deterrent technology. “Nutriband’s FDA Type C Meeting approval for AVERSA(TM) Fentanyl signals agency recognition of the product’s potential to address critical unmet medical needs. The Sept. 18 meeting with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine focuses on Chemistry, Manufacturing, and Controls (‘CMC’) plans spanning the entire development and commercialization timeline,” reads a recent article. “This milestone addresses the complete development arc from IND submission through 505(b)(2) NDA approval. The 505(b)(2) pathway allows Nutriband to leverage existing fentanyl safety data while focusing…

WednesdaySep 10, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation

Recent warrant exercises at $6.43 generated $5.3 million, signaling investor conviction in AVERSA(TM) Fentanyl ahead of NDA filing AVERSA(TM) is a abuse-deterrent solution for transdermal patches, addressing a longstanding gap in pain management safety Strategic funding positions Nutriband to complete development and FDA submission, targeting $80–200 million in peak U.S. annual sales The pharmaceutical sector is defined by a critical balance between innovation and validation. Breakthroughs can take years of research, but they only achieve true market credibility when investors, partners, or acquirers signal confidence in commercial potential. For companies tackling complex problems like opioid abuse, that validation becomes especially…

MondaySep 08, 2025 11:15 am

Nutriband Inc. (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology at Emerging Growth Conference

Nutriband sustains itself through multiple revenue-generating subsidiaries At the core of the company’s innovation is the AVERSA(TM) platform, a proprietary abuse-deterrent transdermal technology AVERSA(TM) fentanyl is projected to achieve peak annual sales of $200 million upon FDA approval, with upside potential exceeding $800 million The opioid crisis continues to highlight the urgent need for safer, more secure drug delivery methods, and Nutriband (NASDAQ: NTRB) is positioning itself as a company with a solution. At the August 2025 Emerging Growth Conference, Nutriband founder and president Serguei Melnik detailed the company’s lead product, AVERSA(TM), an abuse-deterrent transdermal technology that integrates aversive agents…

Site Search

Company Search

Tag: Nutriband Inc. NTRB